TY - JOUR
T1 - A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
AU - D'Agostino, G.
AU - Del Campo, J.
AU - Mellado, B.
AU - Izquierdo, M. A.
AU - Minarik, T.
AU - Cirri, L.
AU - Marini, L.
AU - Perez-Gracia, J. L.
AU - Scambia, G.
PY - 2006/1
Y1 - 2006/1
N2 - LY355703 is a synthetic product structurally related to the cryptophycin family isolated from the blue-green algae, which exerts a potent destabilization of microtubules during mitosis. This study was performed to determine the activity of LY355703 in patients with platinum-resistant advanced ovarian cancer and to characterize its toxicity profile. Twenty-six patients were enrolled in this study. Resistant disease was defined as a platinum-free interval of 2) was administered intravenously on days 1 and 8, every 3 weeks, infused over 2 h. From 24 patients evaluable for response, three partial responses (12.5%) and seven disease stabilizations were registered (29.2%), for an overall clinical benefit of 41.7%. Fourteen patients (58.3%) experienced a progression of the disease during treatment. Among the 25 patients evaluable for toxicity, two episodes of grade 3 anemia (8%); one, grade 3 thrombocytopenia (4%); one, grade 4 elevation of creatinine (4%); and one, grade 3 hyperbilirubinemia (4%) were reported. LY355703 has a modest activity in patients with platinum-resistant advanced ovarian cancer. Nevertheless, the considerable rate of disease stabilization in the absence of serious adverse events in this poor-prognosis study population suggests that this novel cryptophycin may deserve further investigation in this setting.
AB - LY355703 is a synthetic product structurally related to the cryptophycin family isolated from the blue-green algae, which exerts a potent destabilization of microtubules during mitosis. This study was performed to determine the activity of LY355703 in patients with platinum-resistant advanced ovarian cancer and to characterize its toxicity profile. Twenty-six patients were enrolled in this study. Resistant disease was defined as a platinum-free interval of 2) was administered intravenously on days 1 and 8, every 3 weeks, infused over 2 h. From 24 patients evaluable for response, three partial responses (12.5%) and seven disease stabilizations were registered (29.2%), for an overall clinical benefit of 41.7%. Fourteen patients (58.3%) experienced a progression of the disease during treatment. Among the 25 patients evaluable for toxicity, two episodes of grade 3 anemia (8%); one, grade 3 thrombocytopenia (4%); one, grade 4 elevation of creatinine (4%); and one, grade 3 hyperbilirubinemia (4%) were reported. LY355703 has a modest activity in patients with platinum-resistant advanced ovarian cancer. Nevertheless, the considerable rate of disease stabilization in the absence of serious adverse events in this poor-prognosis study population suggests that this novel cryptophycin may deserve further investigation in this setting.
KW - Cryptophycin
KW - LY355703
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=33645352797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645352797&partnerID=8YFLogxK
U2 - 10.1111/j.1525-1438.2006.00276.x
DO - 10.1111/j.1525-1438.2006.00276.x
M3 - Article
C2 - 16445613
AN - SCOPUS:33645352797
SN - 1048-891X
VL - 16
SP - 71
EP - 76
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 1
ER -